Seagen announces positive topline results of pivotal phase 2 clinical trial of tukysa® (tucatinib) in combination with trastuzumab in her2-positive metastatic colorectal cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced positive topline results from the pivotal phase 2 mountaineer clinical trial investigating tukysa® (tucatinib) in combination with trastuzumab in patients with previously treated her2-positive metastatic colorectal cancer (mcrc). data from this trial will form the basis of a planned supplemental new drug application to the u.s. food and drug administration (fda) under the fda's accelerated approval program. merck, known
SGEN Ratings Summary
SGEN Quant Ranking